No­vo Nordisk plans for life af­ter We­govy, set­ting up roots in Boston to try and find its fu­ture

LEX­ING­TON, Mass. — The world’s sec­ond-most valu­able phar­ma com­pa­ny is on the hunt for its next big break­through, and it thinks the se­quel to Ozem­pic or We­govy could be dis­cov­ered in Boston.

On Wednes­day, the Dan­ish di­a­betes and obe­si­ty drug­mak­er No­vo Nordisk un­veiled its new R&D fa­cil­i­ty just out­side the city, pitch­ing it as a US flag­ship to match its head­quar­ters in Den­mark, and an im­por­tant step to­wards life af­ter its block­buster GLP-1 drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER